Ask AI

Bridging Cancer Discoveries to Practice: CCO’s Independent Conference Highlights From the ESMO 2025 Congress *

Gain expert insights into recent clinical trial data on novel approaches and emerging therapies presented at the ESMO 2025 Congress to personalize care and improve outcomes of patients with solid tumors including breast cancer, lung cancer, and gastrointestinal cancers through a preconference ClinicalThought commentary and, following the meeting, downloadable slides of the key studies and certified text modules with expert viewpoints on the implications of the different studies.

Share

Program Content

Activities

ESMO 2025 Preview
An Expert’s Guide to ESMO 2025: A Preview of the Top Abstracts
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: October 16, 2025

21 Capsule Summaries

Activities

MATTERHORN OS
Phase III MATTERHORN: Final OS and EFS by Pathologic Outcomes With Durvalumab + FLOT vs Placebo + FLOT in Resectable Gastric/GEJ Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 21, 2025

DESTINY-Breast05
DESTINY-Breast05: Interim Analysis of a Phase III Trial of Adjuvant T-DXd vs T-DM1 for High-Risk HER2+ EBC With Residual Invasive Disease After Neoadjuvant Therapy
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 23, 2025

FLAURA2 OS Subgroup
FLAURA2: OS Outcomes by Baseline Prognostic Factors in EGFR-Mutated NSCLC Receiving 1L Osimertinib ± Platinum-Based CT
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 23, 2025

TROPION-Breast02
TROPION-Breast02: Dato-DXd vs Investigator’s Choice of CT as 1L Treatment in Patients With TNBC Who Are Not Candidates for Immunotherapy
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 24, 2025

ASCENT-03
ASCENT-03: Phase III Trial of 1L Sacituzumab Govitecan vs Chemotherapy for Patients With Advanced TNBC Ineligible for PD-1/PD-L1 Inhibitors
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 24, 2025

DESTINY-Breast11
DESTINY-Breast11: Phase III Study of Neoadjuvant T-DXd With or Without THP vs ddAC-THP in Patients With High-Risk HER2+ EBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 24, 2025

MDT BRIDGE
MDT-BRIDGE: Phase II Trial of Neoadjuvant Durvalumab + CT and Subsequent Surgery + Adjuvant Durvalumab or CRT + Consolidation Durvalumab for Resectable Stage IIB-IIIB NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 24, 2025

First-line Zongertinib
Beamion LUNG-1: Phase I Study of Zongertinib as First-line Treatment for Advanced HER2-Mutant NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 27, 2025

HARMONi 6
HARMONi-6: Ivonescimab + CT vs Tislelizumab + CT as 1L Therapy for Stage IIIB-IV Squamous NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 27, 2025

monarchE Primary OS Analysis
monarchE: Primary Analysis of OS With Adjuvant Abemaciclib Plus ET in Patients With High-Risk, Node-Positive, HR+/HER2- EBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 28, 2025

ASCENT 04 KEYNOTE D19 PROs
ASCENT-04/KEYNOTE-D19: Patient-Reported Outcomes of 1L Sacituzumab Govitecan vs CT + Pembrolizumab in PD-L1–Positive Advanced TNBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 28, 2025

DeLLphi-303
DeLLphi-303: Phase Ib Study of 1L SoC Chemoimmunotherapy + Tarlatamab in Extensive-Stage Small-Cell Lung Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 28, 2025

EDGE Gastric Arm A1
EDGE-Gastric Arm A1 Update: Phase II Trial of Domvanalimab, Zimberelimab, and FOLFOX in Previously Untreated Advanced HER2-Negative GC/GEJC/EAC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 29, 2025

KRAS G12D Inhibitor HRS 4642
Phase I Trial of the KRAS G12D Inhibitor HRS-4642 in Previously Treated Advanced KRAS G12D–Mutant NSCLC and PDAC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 29, 2025

OptiTROP Lung04
OptiTROP-Lung04: Phase III Trial of Sacituzumab Tirumotecan vs Chemotherapy in EGFRm NSCLC After Progression on EGFR-TKIs
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 29, 2025

SOHO-01
SOHO-01: Phase I/II Study of Sevabertinib in Advanced HER2-Mutant NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 30, 2025

VIKTORIA 1 PIK3CA WT
VIKTORIA-1: Gedatolisib + Fulvestrant ± Palbociclib vs Fulvestrant in HR+/HER2- Advanced Breast Cancer With PIK3CA Wild-Type Status
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 31, 2025

evERA BC
evERA BC: Phase III Trial of Giredestrant + Everolimus in Advanced ER+/HER2- Breast Cancer Previously Treated With a CDK4/6 Inhibitor
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 31, 2025

DYNAMIC III ctDNA Negative
DYNAMIC-III: De-escalation of Adjuvant CT in the Postoperative ctDNA-Negative Cohort of Patients With Stage III Colon Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 31, 2025

FORTITUDE-101
FORTITUDE-101: Bemarituzumab + mFOLFOX6 vs Placebo + mFOLFOX6 in Patients With Advanced/Metastatic FGFR2b  -Overexpressing G/GEJ Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 03, 2025

INCB161734
Phase I Trial of the KRAS G12D Inhibitor INCB161734 in Previously Treated KRAS G12D–Mutant Advanced Solid Tumors
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 03, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.